12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Company News  |  Deals

Myriad Genetics, AstraZeneca deal

AstraZeneca will use Myriad's BRACAnalysis test as a companion diagnostic to select patients likely to respond to the pharma's olaparib for enrollment in Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor. Myriad Genetics has submitted an investigational device exemption (IDE) to FDA to use the...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >